In less than a decade, the therapeutic landscape of metabolic medicine has been fundamentally rewritten. What began as a focused effort to manage type 2 diabetes has exploded into a multi-billion-dollar juggernaut, with GLP-1 receptor agonists (GLP-1s) now being deployed against a sprawling roster of chronic conditions. As the "GLP-1 wave" expands from glycemic control and weight management to cardiovascular health, sleep apnea, kidney disease, and Metabolic Dysfunction-Associated Steatohepatitis (MASH), the research community is facing a critical bottleneck: the urgent need for new, highly specific biospecimens to study these complex, systemic effects.
The Evolution of a Drug Class
The trajectory of GLP-1s is defined by a rapid succession of scientific breakthroughs and regulatory milestones. Semaglutide, the cornerstone of this class, was first authorized for type 2 diabetes in 2017. By 2021, its approval for obesity signaled the birth of a new era in weight-loss pharmacology. Since then, the market has matured, with the introduction of dual-agonists like tirzepatide (GIP/GLP-1) and the emergence of next-generation candidates, including amylin and FGF21 mimetics.
The competitive map is no longer dominated solely by the Novo Nordisk and Eli Lilly duopoly. The field is rapidly diversifying to include oral small molecules, monthly injectable formulations, and an influx of innovative contenders from China. Most recently, in April 2026, the FDA approved orforglipron (Foundayo)—the first oral small-molecule GLP-1 for obesity—marking one of the fastest new-drug clearances since 2002.
A Chronology of Expansion
The clinical utility of GLP-1s has widened at a breakneck pace, consistently challenging the limits of traditional metabolic research:
- 2017: Semaglutide (Ozempic) receives initial approval for type 2 diabetes.
- 2021: Semaglutide (Wegovy) is greenlit for chronic weight management.
- 2022: The FDA approves tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist, for diabetes.
- 2023: Tirzepatide (Zepbound) gains approval for obesity.
- March 2024: Wegovy secures a landmark indication to reduce cardiovascular risk in patients with obesity.
- December 2024: Zepbound becomes the first medication approved for obstructive sleep apnea.
- January 2025: Ozempic is authorized to slow the progression of chronic kidney disease.
- August 2025: Wegovy is cleared for the treatment of MASH with moderate-to-advanced fibrosis.
- December 2025: The first oral GLP-1 pill for weight loss hits the market.
- April 2026: Orforglipron (Foundayo) secures approval, heralding a new era of small-molecule oral efficacy.
Economic Implications and Accessibility
The socioeconomic impact of this expansion is profound. As of July 1, 2026, Medicare has begun covering GLP-1s for weight loss, a move that drastically alters the affordability landscape for millions of Americans. Previously, the high cost—often exceeding $1,000 per month—limited access, even as one in eight American adults reported using these drugs for various metabolic conditions. While manufacturer-sponsored discount programs attempted to bridge the gap, the shift toward public coverage marks the final step in cementing these agents as a standard of care.
However, the rapid adoption of these drugs has outpaced the existing infrastructure for biological research. Scientists are no longer merely studying blood glucose; they are investigating the drug’s potential in neurodegeneration, oncological outcomes, and liver fibrosis. This has created a "data and sample gap" where traditional biobanks, built for diabetes research, are struggling to provide the specific, clinically annotated tissues required for these new, complex research questions.
The Specimen Bottleneck: A Call for Innovation
The maturation of GLP-1 research has spurred an unprecedented demand for biospecimens that reflect these new indications. "If you think about what GLP-1s were first developed for, a lot of it was around weight loss," explains Cathie Miller, Ph.D., director of product management operations at BioIVT, a global leader in biospecimen and ADME-Tox services. "The data and specimens collected in the early years were optimized for those specific metabolic endpoints. As the science has evolved, those original samples are no longer sufficient. You cannot study Alzheimer’s or obesity-associated cancers with the archives of a decade ago."
The Pivot from Tissue to Biofluids
The sourcing of human biological samples is shifting as researchers move beyond traditional surgical resections. In many modern indications, obtaining physical tissue is either clinically impossible or ethically fraught. Consequently, there is an industry-wide pivot toward high-quality biofluids.
"Ten years ago, it was predominantly about oncology tissue resections and matched normals," Miller notes. "Today, we are seeing a massive drive toward biofluids—plasma, serum, whole blood, and increasingly, urine, feces, and saliva. We’ve seen our own business shift from a 60/40 tissue-to-biofluid split to a 60/40 biofluid-to-tissue ratio."
This evolution is driven not only by the systemic nature of GLP-1s but also by breakthroughs in liquid biopsy technology, exosome analysis, and a deeper understanding of how systemic disease manifests in non-invasive markers.
Targeted Research: The MASH and Neurodegeneration Frontier
The case of Metabolic Dysfunction-Associated Steatohepatitis (MASH) serves as a prime example of how quickly research needs can change. When the FDA approved Wegovy for MASH in 2025, the requirement for hepatocytes shifted overnight. Researchers no longer needed standard liver cells; they required hepatocytes exhibiting specific disease characteristics, such as elevated liver-fatty scores or markers of advanced fibrosis.
"Sponsors are looking for samples that have specific pathological characteristics," says Brian Ogilvie, Ph.D., vice president of scientific consulting at BioIVT. "It’s about having access to platforms like HEPATOPAC that allow for chronic, fibrotic studies, which are essential for testing the next generation of FGF21-mimic compounds."
Similarly, in the field of neurodegeneration, the difficulty of accessing brain tissue in living patients has made cerebrospinal fluid (CSF) the "gold standard" for research. Even as headline clinical trials—such as the EVOKE and Exenatide-PD3 studies—have faced setbacks regarding clinical efficacy, the demand for high-quality, longitudinal CSF samples remains at an all-time high. Sponsors are desperate to understand why these drugs shift biomarkers for Alzheimer’s and Parkinson’s without necessarily stopping disease progression, necessitating deep, annotated datasets that link biological samples to long-term clinical outcomes.
Bridging the Gap with Clinical Annotation
The value of a modern biospecimen lies less in the physical tissue itself and more in the clinical "story" attached to it. According to Miller, the most valuable samples are those with comprehensive, longitudinal patient histories.
"We are making a concerted effort to map the donor’s journey," Miller explains. "If a donor is on a GLP-1, we want to know their full medical history: past medications, current comorbidities, and whether they ultimately developed an obesity-related cancer, such as colorectal or post-menopausal breast cancer. This level of annotation allows researchers to ask not just ‘what happened?’ but ‘why?’"
Future Implications
The global biospecimen procurement market, valued at $5 billion in 2024, is projected to surge toward $11 billion by 2033. This growth is directly tethered to the ability of biobanks to pivot alongside the pharmaceutical industry’s expanding interest in GLP-1 biology.
The industry is currently at a crossroads. Roughly 80% of researchers report having narrowed the scope of their studies due to the difficulty of obtaining well-annotated, high-quality specimens. To overcome this, the focus must move away from generic collections and toward bespoke, indication-specific biorepositories.
As the GLP-1 wave continues to wash over medical science, the ability to study its effects—from the liver to the brain—will depend entirely on the foresight of the biospecimen industry. The next breakthrough in metabolic medicine will not come from the drug alone, but from the data-rich, clinically annotated samples that allow scientists to uncover the intricate biological mechanisms of this transformative drug class.
About the Author
